Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine‐ and cisplatin‐resistant models
Open Access
- 14 June 2024
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 18 (9) , 2196-2211
Abstract
Gemcitabine plus cisplatin (GC) combination chemotherapy is the primary treatment for advanced bladder cancer (BC) with unresectable or metastatic disease. However, most cases develop resistance to this therapy. We investigated whether drug resistance could be targeted through metabolic reprogramming therapies. Metabolomics analyses in our lab's gemcitabine‐ and cisplatin‐resistant cell lines revealed increased phosphoglycerate dehydrogenase (PHGDH) expression in gemcitabine‐resistant cells compared with parental cells. Isocitrate dehydrogenase 2 (IDH2) gain of function stabilized hypoxia‐inducible factor1α (HIF1α) expression, stimulating aerobic glycolysis. In gemcitabine‐resistant cells, elevated fumaric acid suppressed prolyl hydroxylase domain‐containing protein 2/Egl nine homolog 1 (PHD2) and stabilized HIF1α expression. PHGDH downregulation or inhibition in gemcitabine‐resistant BC cells inhibited their proliferation, migration, and invasion. Cisplatin‐resistant cells showed elevated fatty acid metabolism, upregulating fatty acid synthase (FASN) downstream of tyrosine kinase. Using the fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor erdafitinib, we inhibited malonyl‐CoA production, which is crucial for fatty acid synthesis, and thereby suppressed upregulated HIF1α expression. Combination treatment with NCT503 and erdafitinib synergistically suppressed tumor cell proliferation and induced apoptosis in vitro and in vivo. Understanding these mechanisms could enable innovative BC therapeutic strategies to be developed.Keywords
Funding Information
- Japan Society for the Promotion of Science (21K09404, 22K09452, 22K09507, 22K16792, 22K16820)
This publication has 51 references indexed in Scilit:
- Inhibition of fatty acid synthase (FASN) affects the proliferation and apoptosis of HepG2 hepatoma carcinoma cells via the β-catenin/C-myc signaling pathwayAnnals of Hepatology, 2020
- Glucose-derived acetate and ACSS2 as key players in cisplatin resistance in bladder cancerBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2019
- Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular CarcinomaCell Metabolism, 2019
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerCell, 2018
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial CarcinomaJAMA Oncology, 2017
- MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic CancerCancer Cell, 2017
- Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolismCancer Letters, 2016
- Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticlesAdvanced Drug Delivery Reviews, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylaseCancer Cell, 2005